Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

22 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Immunomodulatory drugs in multiple myeloma: Impact of the SCARMET (Self CARe and MEdication Toxicity) educational intervention on outpatients' knowledge to manage adverse effects.
Périchou J, Ranchon F, Herledan C, Huot L, Larbre V, Carpentier I, Lazareth A, Karlin L, Beny K, Vantard N, Schwiertz V, Caffin AG, Baudouin A, Sesques P, Brisou G, Ghesquières H, Salles G, Rioufol C. Périchou J, et al. Among authors: herledan c. PLoS One. 2020 Dec 4;15(12):e0243309. doi: 10.1371/journal.pone.0243309. eCollection 2020. PLoS One. 2020. PMID: 33275634 Free PMC article. Clinical Trial.
Immunosuppression medication adherence after allogeneic hematopoietic stem cell transplant: Impact of a specialized clinical pharmacy program.
Charra F, Philippe M, Herledan C, Caffin AG, Larbre V, Baudouin A, Schwiertz V, Vantard N, Labussiere-Wallet H, Ducastelle-Leprêtre S, Barraco F, Balsat M, Larcher MV, Salles G, Rioufol C, Ranchon F. Charra F, et al. Among authors: herledan c. J Oncol Pharm Pract. 2021 Mar 8:10781552211000115. doi: 10.1177/10781552211000115. Online ahead of print. J Oncol Pharm Pract. 2021. PMID: 33683151
Clinical and economic impact of clinical oncology pharmacy in cancer patients receiving injectable anticancer treatments: a systematic review.
Lattard C, Baudouin A, Larbre V, Herledan C, Cerutti A, Cerfon MA, Kimbidima R, Caffin AG, Vantard N, Schwiertz V, Ranchon F, Rioufol C. Lattard C, et al. Among authors: herledan c. J Cancer Res Clin Oncol. 2023 Aug;149(10):7905-7924. doi: 10.1007/s00432-023-04630-4. Epub 2023 Feb 28. J Cancer Res Clin Oncol. 2023. PMID: 36853384
Preparations of exploration of immediate hypersensitivity to antineoplastic agents: An oncology pharmacy perspective.
Dubromel A, Caffin AG, Hacard F, Vantard N, Baudouin A, Herledan C, Larbre V, Schwiertz V, Nosbaum A, Pralong P, Nicolas JF, Berard F, Rioufol C, Ranchon F. Dubromel A, et al. Among authors: herledan c. J Oncol Pharm Pract. 2022 Oct;28(7):1552-1559. doi: 10.1177/10781552211035695. Epub 2021 Sep 21. J Oncol Pharm Pract. 2022. PMID: 34546819
22 results